TR200100066T2 - Göz enfeksiyonlarının tedavisi için oksazolidinonlar. - Google Patents

Göz enfeksiyonlarının tedavisi için oksazolidinonlar.

Info

Publication number
TR200100066T2
TR200100066T2 TR2001/00066T TR200100066T TR200100066T2 TR 200100066 T2 TR200100066 T2 TR 200100066T2 TR 2001/00066 T TR2001/00066 T TR 2001/00066T TR 200100066 T TR200100066 T TR 200100066T TR 200100066 T2 TR200100066 T2 TR 200100066T2
Authority
TR
Turkey
Prior art keywords
treatment
oxazolidinones
eye infections
treating
effective amount
Prior art date
Application number
TR2001/00066T
Other languages
English (en)
Inventor
Cochran Robert
W. Ford Charles
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of TR200100066T2 publication Critical patent/TR200100066T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bu bulus, tedaviye ihtiyaci olan yararli bir sicak kanli memelide, bir göz enfeksiyonunu tedavi etmeye mahsus bir yöntemle ilgili olup, bu yöntem, bir oksazolidinon bilesiginin oftalmik açidan etkili bir miktarinin lokal olarak tatbik edilmesini içerir.
TR2001/00066T 1998-07-14 1999-07-07 Göz enfeksiyonlarının tedavisi için oksazolidinonlar. TR200100066T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9276598P 1998-07-14 1998-07-14

Publications (1)

Publication Number Publication Date
TR200100066T2 true TR200100066T2 (tr) 2001-05-21

Family

ID=22235050

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00066T TR200100066T2 (tr) 1998-07-14 1999-07-07 Göz enfeksiyonlarının tedavisi için oksazolidinonlar.

Country Status (27)

Country Link
US (2) US6337329B1 (tr)
EP (1) EP1096934B1 (tr)
JP (1) JP2002520359A (tr)
KR (1) KR20010079530A (tr)
CN (1) CN1305374A (tr)
AT (1) ATE304886T1 (tr)
AU (1) AU740781B2 (tr)
BG (1) BG64666B1 (tr)
BR (1) BR9912004A (tr)
CA (1) CA2334811A1 (tr)
DE (1) DE69927380T2 (tr)
DK (1) DK1096934T3 (tr)
EA (1) EA003274B1 (tr)
EE (1) EE200100026A (tr)
ES (1) ES2249020T3 (tr)
HU (1) HUP0102836A3 (tr)
ID (1) ID27276A (tr)
IL (1) IL140769A0 (tr)
NO (1) NO20010202D0 (tr)
NZ (1) NZ509375A (tr)
PL (1) PL345544A1 (tr)
PT (1) PT1096934E (tr)
SG (1) SG125079A1 (tr)
SK (1) SK20332000A3 (tr)
TR (1) TR200100066T2 (tr)
WO (1) WO2000003710A1 (tr)
ZA (1) ZA200100038B (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR020660A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
JP2003529544A (ja) * 1999-09-13 2003-10-07 インサイト・ビジョン・インコーポレイテッド 眼感染症の予防たのための局所処置
US6562820B2 (en) * 2000-07-05 2003-05-13 Pharmacia & Upjohn Company Method for treatment and prevention of mastitis
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US20030069235A1 (en) * 2001-09-14 2003-04-10 J. Greg Slatter Treatment for ocular infections
MXPA04008173A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
TW201043267A (en) * 2009-03-19 2010-12-16 Intervet Int Bv In situ constituting a vaccine for administration to a predetermined herd of animals
CN101766628B (zh) * 2010-01-20 2012-07-04 广东宏盈科技有限公司 一种眼科外用抗细菌感染药物
WO2014043576A1 (en) * 2012-09-13 2014-03-20 Starpharma Pty Limited Method of treatment or prophylaxis of infections of the eye

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164510A (en) 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
KR100257418B1 (ko) * 1991-11-01 2000-05-15 로렌스 티. 마이젠헬더 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DK0730591T3 (da) 1993-11-22 2000-01-31 Upjohn Co Estere af substituerede hydroxyacetyl-piperazin-phenyl-oxazolidinoner
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
HUP9901628A3 (en) * 1996-05-31 2002-11-28 Scripps Research Inst Methods and compositions useful for inhibition of alfa v beta5 mediated angiogenesis

Also Published As

Publication number Publication date
NO20010202L (no) 2001-01-12
EE200100026A (et) 2002-06-17
EP1096934B1 (en) 2005-09-21
NZ509375A (en) 2003-11-28
CA2334811A1 (en) 2000-01-27
ES2249020T3 (es) 2006-03-16
HUP0102836A3 (en) 2003-12-29
DE69927380D1 (de) 2005-10-27
EA200100133A1 (ru) 2001-06-25
KR20010079530A (ko) 2001-08-22
AU740781B2 (en) 2001-11-15
SG125079A1 (en) 2006-09-29
BR9912004A (pt) 2001-04-10
PL345544A1 (en) 2001-12-17
HUP0102836A2 (hu) 2002-05-29
US6740652B2 (en) 2004-05-25
EP1096934A1 (en) 2001-05-09
AU4953099A (en) 2000-02-07
US20020065280A1 (en) 2002-05-30
DE69927380T2 (de) 2006-07-06
JP2002520359A (ja) 2002-07-09
BG105142A (en) 2001-10-31
PT1096934E (pt) 2005-11-30
SK20332000A3 (sk) 2001-05-10
ATE304886T1 (de) 2005-10-15
IL140769A0 (en) 2002-02-10
EA003274B1 (ru) 2003-04-24
ID27276A (id) 2001-03-22
NO20010202D0 (no) 2001-01-12
BG64666B1 (bg) 2005-11-30
CN1305374A (zh) 2001-07-25
WO2000003710A1 (en) 2000-01-27
US6337329B1 (en) 2002-01-08
DK1096934T3 (da) 2005-11-28
ZA200100038B (en) 2002-01-02

Similar Documents

Publication Publication Date Title
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
TR200100066T2 (tr) Göz enfeksiyonlarının tedavisi için oksazolidinonlar.
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
DE60101265D1 (de) Behandlung von augenschmerzen
ATE457171T1 (de) Kombinationstherapie substituierter oxazolidinone
ES2166381T3 (es) Tratamiento de enfermedades vasculares hiperproliferativas.
TR200003280T2 (tr) Katarakt çıkarma için cerrahi prosedürlerin kolaylaştırılması için bir vital boyanın kullanımı.
BR9814923A (pt) Método para tratamento de doença de alzheimer
DK1301201T3 (da) Behandling af glycogenosis type II
EA200101089A1 (ru) Новый способ лечения
NO883306D0 (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
TR200102864T2 (tr) N”rolojik ya da n”ropsikiyatrik bozukluklarìn tedavisi i‡in y”ntem
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DK1305037T3 (da) Smertestillende medikament
TR199902094T2 (tr) 3-Heteroareil-4(3H)-kinazolinonlarin atropizomerleri.
DE69531459D1 (de) Elatase-inhibitoren
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
SE9904289D0 (sv) Method and camposition for the treatment of adenovairal ocular infections
DE60336063D1 (de) Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
EA200100010A1 (ru) Местное применение оксазолидинонов для трансдермальной доставки
TR200202033T2 (tr) Epilepsi Tedavisi İçin Terkipler ve Yöntemler
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
TR200003084T2 (tr) Paroxetine askorbat
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin